411
Participants
Start Date
December 31, 2014
Primary Completion Date
December 31, 2021
Study Completion Date
April 30, 2024
Stereotactic radiotherapy (16 Gray or Sham)
Participants will be allocated in a 2:1 ratio to either 16 Gray SRT (IRay, Oraya, Newark,USA) delivered in a single session, or sham SRT.
0.5 mg ranibizumab
Both arms will receive intravitreal injections of 0.5 mg ranibizumab at baseline, and then administered 'as required' (PRN) up to monthly, if predefined retreatment criteria are met.
Bristol Eye Hospital, Bristol
Hinchingbrooke Hospital, Huntingdon
The Princess Alexandra Hospital, Harlow
Maidstone Hospital, Maidstone
Ashford William Harvey Hospital, Willesborough
James Paget University Hospital, Great Yarmouth
Royal Hallamshire Hospital, Sheffield
Frimley Park Hospital, Frimley
Stoke Mandeville Hospital, Aylesbury
Heart Of England NHS Foundation Trust, Birmingham
Royal Blackburn Hospital, Blackburn
Sussex Eye Hospital, Brighton
Addenbrooke's Hospital, Cambridge
Essex County Hospital, Colchester
Leighton Hospital, Crewe
Royal Derby Hospital, Derby
Dorset County Hospital, Dorchester
Calderdale Royal Hospital, Halifax
Whipps Cross Hospital, Leytonstone
Lincoln Country Hospital, Lincoln
Central Middlesex Hospital, London
King's College Hospital NHS Foundation Trust, London
Epsom and St. Helier Hospital, London
Manchester Royal Eye Hospital, Manchester
Norfolk & Norwich University Hospital, Norwich
Queen's Hospital, Romford
Salisbury District Hospital, Salisbury
Hillingdon Hospital, Uxbridge
New Cross Hospital, Wolverhampton
Yeovil District Hospital, Yeovil
King's College London
OTHER
King's College Hospital NHS Trust
OTHER